Search
for
Sort by
Research 871–900 of 1000+
- Regulation of stem cell function by protein ubiquitylation
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- Myeloproliferative disorder associated with alopecia universalis
- COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients.
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Patient preferences in the treatment of alopecia areata: A review of the literature
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Alopecia Areata
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
- Spontaneous complete resolution of alopecia totalis post SARS-CoV-2 infection
- Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review
- Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
- Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
- Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials